Evidence
What is demonstrated, what is assumed, and what remains unsupported?
Independent pre-diligence
Turn promising science into a diligence-ready venture.
We assess the evidence, surface the risks, and help founders build a case that investors can evaluate and defend.
Science & IP
Founding team
& narrative
& narrative
Market thesis
Commercial traction
Investment readiness
Risk & execution
VSLExperienced
judgment
judgment
Decision-ready directionThe clearest path to the next milestone
01Built for science-based ventures
02Domain-led, not generic mentoring
03Usable outputs, not another checklist
The gap we close
Promising science can still be difficult to underwrite.
Investor interest is not investor conviction. A venture moves forward when an investment analyst, scout, or internal champion can explain the evidence, defend the risks, and show how the next milestone changes the investment case.
Technical founders often receive fragmented advice. VSL connects the science, market, regulatory path, commercial traction, team, and financing plan into one investment logic.
The Venture Stage Lens
One venture.
Six connected lenses.
We examine the case as an investor would: as a system of claims, evidence, dependencies, and risks.
Market logic
Who needs this, who pays, and what proves the urgency is real?
Risk
Which technical, regulatory, commercial, and adoption risks shape the decision?
Execution
Can this team reach the next value-inflecting milestone with the proposed plan?
Financing
Does the raise create a more valuable and financeable company?
Investment logic
Can an investor explain and defend the case when the founder leaves the room?
From finding to fix
We do not hand founders another list of work.
Every priority is paired with the structure, example, or first draft needed to move forward.
- The precise conviction blocker
- Why it matters to an investor
- The evidence needed to resolve it
- An example and template showing what good looks like
- A practical first step or draft structure
Nerava Health / Conviction mapIllustrative output
Priority finding
The €1.5M clinical plan is not yet connected to regulatory clearance, hospital adoption, or the next round.
42patients in a single-site feasibility study
2interested hospitals with no signed study agreements
18 mo.runway expected from the proposed seed round
Why it matters
Two hospital innovation teams have responded positively, but neither conversation has a defined owner, study agreement, timeline, or next decision. Investors cannot distinguish clinical interest from institutional commitment.
What needs to become true
Define a clinically meaningful primary endpoint aligned with the intended use. If 30-day unplanned readmission is retained, specify the patient population, comparator, baseline event rate, target absolute effect, and a powered analysis plan. Treat readmission as exploratory for a 42-patient feasibility study unless the numbers support otherwise. Convert hospital interest into three execution-ready sites. Complete an independent regulatory strategy and build a hospital adoption case identifying the clinical champion, economic buyer, budget source, workflow impact, expected ROI, and evidence supporting the proposed price.
Here is a template for thatClinical-to-investment milestone mapEndpoint to regulatory claim to adoption proof to next financing triggerClinical milestone map.pptx
6-slide editable template, request accessPPTX
6-slide editable template, request accessPPTX
Give every venture a consistent standard of investor preparation.
The VSL Investor Readiness Sprint prepares a focused cohort of science-based ventures for investor scrutiny without adding another generic workshop.
For each founder
Three priority blockers, practical examples, a working session, and revised investor-facing material.
For your program
A consistent assessment method, cohort-level insight, and clearer evidence of founder progress.
At the end
Founders leave with stronger materials and a focused evidence plan.
For founders
Start with an Investor Conviction Snapshot.
Share your deck or one-pager and tell us what you believe is holding investors back. We compare your hypothesis with what your materials communicate.
Request a snapshotPrefer a quick reality check first?
Take the free Founder Delusion IndexYour directional output
- 01One potential conviction risk
- 02Why it matters
- 03One practical action
- 04What still requires deeper review
A focused first view, not a generic deck score or a substitute for full pre-diligence.
Domain experts. Investor mindset.
Built for ventures where the science and investment case must hold together.
Venture Stage Lens brings together experience across scientific innovation, venture building, healthcare, non-health biotechnology, food systems, climate tech, and realistic AI implementation in biotech.
We translate complex technical potential into structured, decision-useful evidence while helping programs see where support will create the greatest change.
Meet the teamStart with the venture in front of you
See what is creating conviction and what still stands in its way.
Independent pre-diligence
Turn promising science into a diligence-ready venture.
We assess the evidence, surface the risks, and help founders build a case that investors can evaluate and defend.
Science & IP
Founding team
& narrative
& narrative
Market thesis
Commercial traction
Investment readiness
Risk & execution
VSLExperienced
judgment
judgment
Decision-ready directionThe clearest path to the next milestone
01Built for science-based ventures
02Domain-led, not generic mentoring
03Usable outputs, not another checklist
The gap we close
Promising science can still be difficult to underwrite.
Investor interest is not investor conviction. A venture moves forward when an investment analyst, scout, or internal champion can explain the evidence, defend the risks, and show how the next milestone changes the investment case.
Technical founders often receive fragmented advice. VSL connects the science, market, regulatory path, commercial traction, team, and financing plan into one investment logic.
The Venture Stage Lens
One venture.
Six connected lenses.
We examine the case as an investor would: as a system of claims, evidence, dependencies, and risks.
Evidence
What is demonstrated, what is assumed, and what remains unsupported?
Market logic
Who needs this, who pays, and what proves the urgency is real?
Risk
Which technical, regulatory, commercial, and adoption risks shape the decision?
Execution
Can this team reach the next value-inflecting milestone with the proposed plan?
Financing
Does the raise create a more valuable and financeable company?
Investment logic
Can an investor explain and defend the case when the founder leaves the room?
From finding to fix
We do not hand founders another list of work.
Every priority is paired with the structure, example, or first draft needed to move forward.
- The precise conviction blocker
- Why it matters to an investor
- The evidence needed to resolve it
- An example and template showing what good looks like
- A practical first step or draft structure
Nerava Health / Conviction mapIllustrative output
Priority finding
The €1.5M clinical plan is not yet connected to regulatory clearance, hospital adoption, or the next round.
42patients in a single-site feasibility study
2interested hospitals with no signed study agreements
18 mo.runway expected from the proposed seed round
Why it matters
Two hospital innovation teams have responded positively, but neither conversation has a defined owner, study agreement, timeline, or next decision. Investors cannot distinguish clinical interest from institutional commitment.
What needs to become true
Define a clinically meaningful primary endpoint aligned with the intended use. If 30-day unplanned readmission is retained, specify the patient population, comparator, baseline event rate, target absolute effect, and a powered analysis plan. Treat readmission as exploratory for a 42-patient feasibility study unless the numbers support otherwise. Convert hospital interest into three execution-ready sites. Complete an independent regulatory strategy and build a hospital adoption case identifying the clinical champion, economic buyer, budget source, workflow impact, expected ROI, and evidence supporting the proposed price.
Here is a template for thatClinical-to-investment milestone mapEndpoint to regulatory claim to adoption proof to next financing triggerClinical milestone map.pptx
6-slide editable template, request accessPPTX
6-slide editable template, request accessPPTX
Give every venture a consistent standard of investor preparation.
The VSL Investor Readiness Sprint prepares a focused cohort of science-based ventures for investor scrutiny without adding another generic workshop.
For each founder
Three priority blockers, practical examples, a working session, and revised investor-facing material.
For your program
A consistent assessment method, cohort-level insight, and clearer evidence of founder progress.
At the end
Founders leave with stronger materials and a focused evidence plan.
For founders
Start with an Investor Conviction Snapshot.
Share your deck or one-pager and tell us what you believe is holding investors back. We compare your hypothesis with what your materials communicate.
Request a snapshotPrefer a quick reality check first?
Take the free Founder Delusion IndexYour directional output
- 01One potential conviction risk
- 02Why it matters
- 03One practical action
- 04What still requires deeper review
A focused first view, not a generic deck score or a substitute for full pre-diligence.
Domain experts. Investor mindset.
Built for ventures where the science and investment case must hold together.
Venture Stage Lens brings together experience across scientific innovation, venture building, healthcare, non-health biotechnology, food systems, climate tech, and realistic AI implementation in biotech.
We translate complex technical potential into structured, decision-useful evidence while helping programs see where support will create the greatest change.
Meet the teamStart with the venture in front of you